These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 29487401)

  • 1. Are immunotherapies for Huntington's disease a realistic option?
    Denis HL; Lauruol F; Cicchetti F
    Mol Psychiatry; 2019 Mar; 24(3):364-377. PubMed ID: 29487401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapies in Huntington's disease and α-Synucleinopathies.
    Fatoba O; Ohtake Y; Itokazu T; Yamashita T
    Front Immunol; 2020; 11():337. PubMed ID: 32161599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunomodulatory Strategies for Huntington's Disease Treatment.
    Colpo GD; Rocha NP; Stimming EF; Teixeira AL
    CNS Neurol Disord Drug Targets; 2017; 16(8):936-944. PubMed ID: 28606048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treating the whole body in Huntington's disease.
    Carroll JB; Bates GP; Steffan J; Saft C; Tabrizi SJ
    Lancet Neurol; 2015 Nov; 14(11):1135-42. PubMed ID: 26466780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interrupting sequence variants and age of onset in Huntington's disease: clinical implications and emerging therapies.
    Wright GEB; Black HF; Collins JA; Gall-Duncan T; Caron NS; Pearson CE; Hayden MR
    Lancet Neurol; 2020 Nov; 19(11):930-939. PubMed ID: 33098802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodies.
    Wolfgang WJ; Miller TW; Webster JM; Huston JS; Thompson LM; Marsh JL; Messer A
    Proc Natl Acad Sci U S A; 2005 Aug; 102(32):11563-8. PubMed ID: 16061794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Molecular therapeutic strategies for Huntington's disease].
    Milewski M; Hoffman-Zacharska D; Ball J
    Postepy Biochem; 2015; 61(1):18-24. PubMed ID: 26281350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic options for Huntington's disease.
    Grimbergen YA; Roos RA
    Curr Opin Investig Drugs; 2003 Jan; 4(1):51-4. PubMed ID: 12625029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disruption of immune cell function by mutant huntingtin in Huntington's disease pathogenesis.
    Andre R; Carty L; Tabrizi SJ
    Curr Opin Pharmacol; 2016 Feb; 26():33-8. PubMed ID: 26461267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in Huntington's disease: implications for experimental therapeutics.
    Feigin A; Zgaljardic D
    Curr Opin Neurol; 2002 Aug; 15(4):483-9. PubMed ID: 12151847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Huntington's disease: Managing neuropsychiatric symptoms in Huntington's disease.
    Loi SM; Walterfang M; Velakoulis D; Looi JC
    Australas Psychiatry; 2018 Aug; 26(4):376-380. PubMed ID: 29687724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The choreography of neuroinflammation in Huntington's disease.
    Crotti A; Glass CK
    Trends Immunol; 2015 Jun; 36(6):364-73. PubMed ID: 26001312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcriptional dysregulation of inflammatory/immune pathways after active vaccination against Huntington's disease.
    Ramsingh AI; Manley K; Rong Y; Reilly A; Messer A
    Hum Mol Genet; 2015 Nov; 24(21):6186-97. PubMed ID: 26307082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The therapeutic potential of intrabodies in neurologic disorders: focus on Huntington and Parkinson diseases.
    Messer A; McLear J
    BioDrugs; 2006; 20(6):327-33. PubMed ID: 17176119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hope for Huntington's disease patients: first clinical gene silencing study in progress].
    Rollnik JD
    Fortschr Neurol Psychiatr; 2017 Aug; 85(8):463-466. PubMed ID: 28841744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Huntington's disease: new hope for therapeutics.
    McMurray CT
    Trends Neurosci; 2001 Nov; 24(11 Suppl):S32-8. PubMed ID: 11881743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intrabodies as neuroprotective therapeutics.
    Messer A; Joshi SN
    Neurotherapeutics; 2013 Jul; 10(3):447-58. PubMed ID: 23649691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmaceutical, cellular and genetic therapies for Huntington's disease.
    Handley OJ; Naji JJ; Dunnett SB; Rosser AE
    Clin Sci (Lond); 2006 Jan; 110(1):73-88. PubMed ID: 16336206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Huntington's disease: a bimolecular vision].
    Fernandes Leite J
    Rev Neurol; 2001 Apr 16-30; 32(8):762-7. PubMed ID: 11391514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutant Huntingtin Does Not Affect the Intrinsic Phenotype of Human Huntington's Disease T Lymphocytes.
    Miller JR; Träger U; Andre R; Tabrizi SJ
    PLoS One; 2015; 10(11):e0141793. PubMed ID: 26529236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.